EchoLaser cleared by the FDA for BPH treatment

EchoLaser has just been specifically cleared by the FDA for BPH treatment (performed transperineally). The so called “tool indication” (soft tissue ablation in urology) remains, making EchoLaser a unique device for multiple use in urology. The specific BPH indication follows the recent mention of TPLA (transperineal laser ablation) in the 2026 AUA guidelines: the combination of these two major milestones opens new possibilities and opportunities for market access and commercial success of EchoLaser in USA.